Histone acetyltransferase mediated regulation of FOXP3 acetylation and Treg function

Current Opinion in Immunology

Volumn 22, Issue 5, 2010, Pages 583-591

  Xiao, Yan ^a   Li, Bin ^b   Zhou, Zhaocai ^c   Hancock, Wayne W ^a   Zhang, Hongtao ^a   Greene, Mark I ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b INSTITUTE PASTEUR OF SHANGHAI   (China)

^c INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE ACETYLTRANSFERASE; PROTEIN P300; SIRTUIN 1; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR FOXP2; TRANSCRIPTION FACTOR FOXP3; TRANSCRIPTION FACTOR NFAT; TRANSCRIPTION FACTOR RUNX1;

ACETYLATION; AMINO TERMINAL SEQUENCE; BINDING AFFINITY; CELL FUNCTION; CELL MATURATION; CELLULAR IMMUNITY; GENE EXPRESSION REGULATION; GENE LOCUS; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; IPEX SYNDROME; NONHUMAN; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN MODIFICATION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; PROTEIN STRUCTURE; REGULATORY T LYMPHOCYTE; REVIEW; TRANSCRIPTION REGULATION; UBIQUITINATION;

ACETYLATION; ANIMALS; FORKHEAD TRANSCRIPTION FACTORS; HISTONE ACETYLTRANSFERASES; HUMANS; LYMPHOCYTE ACTIVATION; T-LYMPHOCYTES, REGULATORY;

EID: 78049240315     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coi.2010.08.013     Document Type: Review

References (88)

1. Maloy K.J., Powrie F. Regulatory T cells in the control of immune pathology. Nat Immunol 2001, 2:816-822.
2. Sakaguchi S., Miyara M., Costantino C.M., Hafler D.A. FOXP3(+) regulatory T cells in the human immune system. Nat Rev Immunol 2010, 10:490-500.
3. Fontenot J.D., Gavin M.A., Rudensky A.Y. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003, 4:330-336.
4. Hori S., Nomura T., Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003, 299:1057-1061.
5. Schubert L.A., Jeffery E., Zhang Y., Ramsdell F., Ziegler S.F. Scurfin (FOXP3) acts as a repressor of transcription and regulates T cell activation. J Biol Chem 2001, 276:37672-37679.
6. Clark L.B., Appleby M.W., Brunkow M.E., Wilkinson J.E., Ziegler S.F., Ramsdell F. Cellular and molecular characterization of the scurfy mouse mutant. J Immunol 1999, 162:2546-2554.
7. Bennett C.L., Christie J., Ramsdell F., Brunkow M.E., Ferguson P.J., Whitesell L., Kelly T.E., Saulsbury F.T., Chance P.F., Ochs H.D. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 2001, 27:20-21.
8. Wildin R.S., Ramsdell F., Peake J., Faravelli F., Casanova J.L., Buist N., Levy-Lahad E., Mazzella M., Goulet O., Perroni L., et al. X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat Genet 2001, 27:18-20.
9. Ormandy L.A., Hillemann T., Wedemeyer H., Manns M.P., Greten T.F., Korangy F. Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res 2005, 65:2457-2464.
10. Wang H.Y., Wang R.F. Regulatory T cells and cancer. Curr Opin Immunol 2007, 19:217-223.
11. Fujimoto S., Greene M., Sehon A.H. Immunosuppressor T cells in tumor bearing host. Immunol Commun 1975, 4:201-217.
12. Perry L.L., Greene M.I. T cell subset interactions in the regulation of syngeneic tumor immunity. Fed Proc 1981, 40:39-44.
13. Samanta A., Li B., Song X., Bembas K., Zhang G., Katsumata M., Saouaf S.J., Wang Q., Hancock W.W., Shen Y., et al. TGF-beta and IL-6 signals modulate chromatin binding and promoter occupancy by acetylated FOXP3. Proc Natl Acad Sci USA 2008, 105:14023-14027.
14. van Loosdregt J., Vercoulen Y., Guichelaar T., Gent Y.Y., Beekman J.M., van Beekum O., Brenkman A.B., Hijnen D.J., Mutis T., Kalkhoven E., et al. Regulation of Treg functionality by acetylation-mediated Foxp3 protein stabilization. Blood 2010, 115:965-974.
15. Li B., Greene M.I. FOXP3 actively represses transcription by recruiting the HAT/HDAC complex. Cell Cycle 2007, 6:1432-1436.
16. Li B., Samanta A., Song X., Iacono K.T., Bembas K., Tao R., Basu S., Riley J.L., Hancock W.W., Shen Y., et al. FOXP3 interactions with histone acetyltransferase and class II histone deacetylases are required for repression. Proc Natl Acad Sci USA 2007, 104:4571-4576.
17. Brunkow M.E., Jeffery E.W., Hjerrild K.A., Paeper B., Clark L.B., Yasayko S.A., Wilkinson J.E., Galas D., Ziegler S.F., Ramsdell F. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet 2001, 27:68-73.
18. Walker M.R., Kasprowicz D.J., Gersuk V.H., Benard A., Van Landeghen M., Buckner J.H., Ziegler S.F. Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25-T cells. J Clin Invest 2003, 112:1437-1443.
19. Zhou Z., Song X., Li B., Greene M.I. FOXP3 and its partners: structural and biochemical insights into the regulation of FOXP3 activity. Immunol Res 2008, 42:19-28.
20. Zhou Z., Song X., Berezov A., Li B., Greene M.I. Structural aspects of the FOXP3 regulatory complex as an immunopharmacological target. Int Immunopharmacol 2009, 9:518-520.
21. Ziegler S.F. FOXP3: of mice and men. Annu Rev Immunol 2006, 24:209-226.
22. Allan S.E., Passerini L., Bacchetta R., Crellin N., Dai M., Orban P.C., Ziegler S.F., Roncarolo M.G., Levings M.K. The role of 2 FOXP3 isoforms in the generation of human CD4+ Tregs. J Clin Invest 2005, 115:3276-3284.
23. Ono M., Yaguchi H., Ohkura N., Kitabayashi I., Nagamura Y., Nomura T., Miyachi Y., Tsukada T., Sakaguchi S. Foxp3 controls regulatory T-cell function by interacting with AML1/Runx1. Nature 2007, 446:685-689.
24. Jain J., Loh C., Rao A. Transcriptional regulation of the IL-2 gene. Curr Opin Immunol 1995, 7:333-342.
25. Rooney J.W., Sun Y.L., Glimcher L.H., Hoey T. Novel NFAT sites that mediate activation of the interleukin-2 promoter in response to T-cell receptor stimulation. Mol Cell Biol 1995, 15:6299-6310.
26. Chatila T.A., Blaeser F., Ho N., Lederman H.M., Voulgaropoulos C., Helms C., Bowcock A.M. JM2, encoding a fork head-related protein, is mutated in X-linked autoimmunity-allergic disregulation syndrome. J Clin Invest 2000, 106:R75-81.
27. Wildin R.S., Smyk-Pearson S., Filipovich A.H. Clinical and molecular features of the immunodysregulation, polyendocrinopathy, enteropathy, X linked (IPEX) syndrome. J Med Genet 2002, 39:537-545.
28. Li B., Samanta A., Song X., Iacono K.T., Brennan P., Chatila T.A., Roncador G., Banham A.H., Riley J.L., Wang Q., et al. FOXP3 is a homo-oligomer and a component of a supramolecular regulatory complex disabled in the human XLAAD/IPEX autoimmune disease. Int Immunol 2007, 19:825-835.
29. Vidali G., Gershey E.L., Allfrey V.G. Chemical studies of histone acetylation. The distribution of epsilon-N-acetyllysine in calf thymus histones. J Biol Chem 1968, 243:6361-6366.
30. Allfrey V.G., Faulkner R., Mirsky A.E. Acetylation and methylation of histones and their possible role in the regulation of RNA synthesis. Proc Natl Acad Sci USA 1964, 51:786-794.
31. Turner B.M. Cellular memory and the histone code. Cell 2002, 111:285-291.
32. Strahl B.D., Allis C.D. The language of covalent histone modifications. Nature 2000, 403:41-45.
33. Gronroos E., Hellman U., Heldin C.H., Ericsson J. Control of Smad7 stability by competition between acetylation and ubiquitination. Mol Cell 2002, 10:483-493.
34. Gu W., Roeder R.G. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 1997, 90:595-606.
35. Imhof A., Yang X.J., Ogryzko V.V., Nakatani Y., Wolffe A.P., Ge H. Acetylation of general transcription factors by histone acetyltransferases. Curr Biol 1997, 7:689-692.
36. LeDizet M., Piperno G. Identification of an acetylation site of Chlamydomonas alpha-tubulin. Proc Natl Acad Sci USA 1987, 84:5720-5724.
37. Carrozza M.J., Utley R.T., Workman J.L., Cote J. The diverse functions of histone acetyltransferase complexes. Trends Genet 2003, 19:321-329.
38. Polevoda B., Sherman F. N-alpha-terminal acetylation of eukaryotic proteins. J Biol Chem 2000, 275:36479-36482.
39. Ogryzko V.V., Schiltz R.L., Russanova V., Howard B.H., Nakatani Y. The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell 1996, 87:953-959.
40. Bannister A.J., Kouzarides T. The CBP co-activator is a histone acetyltransferase. Nature 1996, 384:641-643.
41. Yang X.J., Ogryzko V.V., Nishikawa J., Howard B.H., Nakatani Y. A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A. Nature 1996, 382:319-324.
42. Yang X.J. The diverse superfamily of lysine acetyltransferases and their roles in leukemia and other diseases. Nucleic Acids Res 2004, 32:959-976.
43. Tao R., de Zoeten E.F., Ozkaynak E., Chen C., Wang L., Porrett P.M., Li B., Turka L.A., Olson E.N., Greene M.I., et al. Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat Med 2007, 13:1299-1307.
44. Kamine J., Elangovan B., Subramanian T., Coleman D., Chinnadurai G. Identification of a cellular protein that specifically interacts with the essential cysteine region of the HIV-1 Tat transactivator. Virology 1996, 216:357-366.
45. Legube G., Trouche D. Identification of a larger form of the histone acetyl transferase Tip60. Gene 2003, 310:161-168.
46. Ran Q., Pereira-Smith O.M. Identification of an alternatively spliced form of the Tat interactive protein (Tip60), Tip60(beta). Gene 2000, 258:141-146.
47. Utley R.T., Cote J. The MYST family of histone acetyltransferases. Curr Top Microbiol Immunol 2003, 274:203-236.
48. Ikura T., Ogryzko V.V., Grigoriev M., Groisman R., Wang J., Horikoshi M., Scully R., Qin J., Nakatani Y. Involvement of the TIP60 histone acetylase complex in DNA repair and apoptosis. Cell 2000, 102:463-473.
49. Nordentoft I., Jorgensen P. The acetyltransferase 60 kDa trans-acting regulatory protein of HIV type 1-interacting protein (Tip60) interacts with the translocation E26 transforming-specific leukaemia gene (TEL) and functions as a transcriptional co-repressor. Biochem J 2003, 374:165-173.
50. Xiao H., Chung J., Kao H.Y., Yang Y.C. Tip60 is a co-repressor for STAT3. J Biol Chem 2003, 278:11197-11204.
51. Col E., Caron C., Chable-Bessia C., Legube G., Gazzeri S., Komatsu Y., Yoshida M., Benkirane M., Trouche D., Khochbin S. HIV-1 Tat targets Tip60 to impair the apoptotic cell response to genotoxic stresses. EMBO J 2005, 24:2634-2645.
52. Akhtar A., Zink D., Becker P.B. Chromodomains are protein-RNA interaction modules. Nature 2000, 407:405-409.
53. Gaughan L., Brady M.E., Cook S., Neal D.E., Robson C.N. Tip60 is a co-activator specific for class I nuclear hormone receptors. J Biol Chem 2001, 276:46841-46848.
54. Kimura A., Horikoshi M. Tip60 acetylates six lysines of a specific class in core histones in vitro. Genes Cells 1998, 3:789-800.
55. Gaughan L., Logan I.R., Cook S., Neal D.E., Robson C.N. Tip60 and histone deacetylase 1 regulate androgen receptor activity through changes to the acetylation status of the receptor. J Biol Chem 2002, 277:25904-25913.
56. Patel J.H., Du Y., Ard P.G., Phillips C., Carella B., Chen C.J., Rakowski C., Chatterjee C., Lieberman P.M., Lane W.S., et al. The c-MYC oncoprotein is a substrate of the acetyltransferases hGCN5/PCAF and TIP60. Mol Cell Biol 2004, 24:10826-10834.
57. Sun Y., Jiang X., Chen S., Fernandes N., Price B.D. A role for the Tip60 histone acetyltransferase in the acetylation and activation of ATM. Proc Natl Acad Sci USA 2005, 102:13182-13187.
58. Wang J., Chen J. SIRT1 regulates autoacetylation and histone acetyltransferase activity of TIP60. J Biol Chem 2010, 285:11458-11464.
59. Yamagata K., Kitabayashi I. Sirt1 physically interacts with Tip60 and negatively regulates Tip60-mediated acetylation of H2AX. Biochem Biophys Res Commun 2009, 390:1355-1360.
60. Tang Y., Luo J., Zhang W., Gu W. Tip60-dependent acetylation of p53 modulates the decision between cell-cycle arrest and apoptosis. Mol Cell 2006, 24:827-839.
61. Brady M.E., Ozanne D.M., Gaughan L., Waite I., Cook S., Neal D.E., Robson C.N. Tip60 is a nuclear hormone receptor coactivator. J Biol Chem 1999, 274:17599-17604.
62. Goodman R.H., Smolik S. CBP/p300 in cell growth, transformation, and development. Genes Dev 2000, 14:1553-1577.
63. Chrivia J.C., Kwok R.P., Lamb N., Hagiwara M., Montminy M.R., Goodman R.H. Phosphorylated CREB binds specifically to the nuclear protein CBP. Nature 1993, 365:855-859.
64. Eckner R., Ewen M.E., Newsome D., Gerdes M., DeCaprio J.A., Lawrence J.B., Livingston D.M. Molecular cloning and functional analysis of the adenovirus E1A-associated 300-kD protein (p300) reveals a protein with properties of a transcriptional adaptor. Genes Dev 1994, 8:869-884.
65. Yao T.P., Oh S.P., Fuchs M., Zhou N.D., Ch'ng L.E., Newsome D., Bronson R.T., Li E., Livingston D.M., Eckner R. Gene dosage-dependent embryonic development and proliferation defects in mice lacking the transcriptional integrator p300. Cell 1998, 93:361-372.
66. Kung A.L., Rebel V.I., Bronson R.T., Ch'ng L.E., Sieff C.A., Livingston D.M., Yao T.P. Gene dose-dependent control of hematopoiesis and hematologic tumor suppression by CBP. Genes Dev 2000, 14:272-277.
67. Kawasaki H., Eckner R., Yao T.P., Taira K., Chiu R., Livingston D.M., Yokoyama K.K. Distinct roles of the co-activators p300 and CBP in retinoic-acid-induced F9-cell differentiation. Nature 1998, 393:284-289.
68. Arany Z., Sellers W.R., Livingston D.M., Eckner R. E1A-associated p300 and CREB-associated CBP belong to a conserved family of coactivators. Cell 1994, 77:799-800.
69. Thompson P.R., Wang D., Wang L., Fulco M., Pediconi N., Zhang D., An W., Ge Q., Roeder R.G., Wong J., et al. Regulation of the p300 HAT domain via a novel activation loop. Nat Struct Mol Biol 2004, 11:308-315.
70. Kwok R.P., Lundblad J.R., Chrivia J.C., Richards J.P., Bachinger H.P., Brennan R.G., Roberts S.G., Green M.R., Goodman R.H. Nuclear protein CBP is a coactivator for the transcription factor CREB. Nature 1994, 370:223-226.
71. Blobel G.A. CREB-binding protein and p300: molecular integrators of hematopoietic transcription. Blood 2000, 95:745-755.
72. Xu L., Glass C.K., Rosenfeld M.G. Coactivator and corepressor complexes in nuclear receptor function. Curr Opin Genet Dev 1999, 9:140-147.
73. Korzus E., Torchia J., Rose D.W., Xu L., Kurokawa R., McInerney E.M., Mullen T.M., Glass C.K., Rosenfeld M.G. Transcription factor-specific requirements for coactivators and their acetyltransferase functions. Science 1998, 279:703-707.
74. Tang Y., Zhao W., Chen Y., Zhao Y., Gu W. Acetylation is indispensable for p53 activation. Cell 2008, 133:612-626.
75. Sykes S.M., Mellert H.S., Holbert M.A., Li K., Marmorstein R., Lane W.S., McMahon S.B. Acetylation of the p53 DNA-binding domain regulates apoptosis induction. Mol Cell 2006, 24:841-851.
76. Black J.C., Mosley A., Kitada T., Washburn M., Carey M. The SIRT2 deacetylase regulates autoacetylation of p300. Mol Cell 2008, 32:449-455.
77. de Zoeten E.F., Wang L., Sai H., Dillmann W.H., Hancock W.W. Inhibition of HDAC9 increases T regulatory cell function and prevents colitis in mice. Gastroenterology 2010, 138:583-594.
78. Saouaf S.J., Li B., Zhang G., Shen Y., Furuuchi N., Hancock W.W., Greene M.I. Deacetylase inhibition increases regulatory T cell function and decreases incidence and severity of collagen-induced arthritis. Exp Mol Pathol 2009, 87:99-104.
79. Wang L., de Zoeten E.F., Greene M.I., Hancock W.W. Immunomodulatory effects of deacetylase inhibitors: therapeutic targeting of FOXP3+ regulatory T cells. Nat Rev Drug Discov 2009, 8:969-981.
80. Fujimoto S., Greene M.I., Sehon A.H. Regulation of the immune response to tumor antigens. II. The nature of immunosuppressor cells in tumor-bearing hosts. J Immunol 1976, 116:800-806.
81. Betts G., Twohig J., Van den Broek M., Sierro S., Godkin A., Gallimore A. The impact of regulatory T cells on carcinogen-induced sarcogenesis. Br J Cancer 2007, 96:1849-1854.
82. Curiel T.J., Coukos G., Zou L., Alvarez X., Cheng P., Mottram P., Evdemon-Hogan M., Conejo-Garcia J.R., Zhang L., Burow M., et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004, 10:942-949.
83. Liu V.C., Wong L.Y., Jang T., Shah A.H., Park I., Yang X., Zhang Q., Lonning S., Teicher B.A., Lee C. Tumor evasion of the immune system by converting CD4+CD25-T cells into CD4+CD25+ T regulatory cells: role of tumor-derived TGF-beta. J Immunol 2007, 178:2883-2892.
84. Valzasina B., Piconese S., Guiducci C., Colombo M.P. Tumor-induced expansion of regulatory T cells by conversion of CD4+CD25-lymphocytes is thymus and proliferation independent. Cancer Res 2006, 66:4488-4495.
85. Ghiringhelli F., Puig P.E., Roux S., Parcellier A., Schmitt E., Solary E., Kroemer G., Martin F., Chauffert B., Zitvogel L. Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J Exp Med 2005, 202:919-929.
86. Beyer M., Kochanek M., Giese T., Endl E., Weihrauch M.R., Knolle P.A., Classen S., Schultze J.L. In vivo peripheral expansion of naive CD4+CD25high FoxP3+ regulatory T cells in patients with multiple myeloma. Blood 2006, 107:3940-3949.
87. Perry L.L., Kripke M.L., Benacerraf B., Dorf M.E., Greene M.I. Regulation of the immune response to tumor antigen. VIII. The effects of host specific anti-I-J antibodies on the immune response to tumors of different origin. Cell Immunol 1980, 51:349-359.
88. Drebin J.A., Waltenbaugh C., Schatten S., Benacerraf B., Greene M.I. Inhibition of tumor growth by monoclonal anti-I-J antibodies. J Immunol 1983, 130:506-509.